News
TTIPF
0.400
NaN%
--
Thiogenesis Announces FDA Clearance of IND for Nephropathic Cystinosis
Newsfile · 10/22 09:00
Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update
Newsfile · 09/21 08:00
Thiogenesis Engages Brisco Capital for Investor Relations
Newsfile · 09/03 10:00
Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome
Newsfile · 07/13 10:00
Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors
Newsfile · 06/17 12:00
Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million
Newsfile · 06/03 10:00
Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares
Newsfile · 06/01 18:49
Thiogenesis Announces Non-Brokered Private Placement
Newsfile · 05/11 13:00
Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
Newsfile · 04/16 13:00
Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update
Newsfile · 02/02 14:00
Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026
Newsfile · 01/23 14:00
Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026
Newsfile · 01/13 14:00
Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar
Newsfile · 01/05 14:00
Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis
Newsfile · 11/24/2025 14:00
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis
Newsfile · 11/04/2025 14:00
More
Webull provides a variety of real-time TTIPF stock news. You can receive the latest news about Thiogenesis through multiple platforms. This information may help you make smarter investment decisions.
About TTIPF
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102’s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.